MCM
NDRM

Moore Capital Management’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Moore Capital Management’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-50,000
Closed -$1.11M – 263
2016
Q4 		$1.11M Buy
+50,000
New +$935K 0.04% 145

Other funds holding NDRM

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Moore Capital Management's NDRM Position: Q1 2017 in Review

Moore Capital Management sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q1 2017, closing a stake of 50,000 shares — an estimated $1.11M sold.

Moore Capital Management first reported a position in NDRM in Q4 2016 and held it in 1 quarter. The position peaked at $1.11M in Q4 2016. 70 funds tracked by Wall St. Rank hold NDRM as of Q1 2017.

  • Moore Capital Management reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q1 2017 after selling out during the quarter.
  • Moore Capital Management sold 50,000 NeuroDerm Ltd. Ordinary Shares shares in Q1 2017, an estimated $1.11M.
  • Moore Capital Management first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2016 and held it in 1 quarter.
  • Moore Capital Management's NeuroDerm Ltd. Ordinary Shares position peaked at $1.11M in Q4 2016.
  • 70 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q1 2017.

Based on Moore Capital Management's 13F filing for Q1 2017, filed 15 May 2017.